Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented by the side on which the tumor is located, BRAF status, and MSI-H or dMMR status. Immune checkpoint inhibitors targeting MSI-H / dMMR metastatic colorectal cancer are experiencing uptake and influencing current treatment algorithms. Therapies targeting specific biomarker-defined populations, such as BRAF-mutant metastatic colorectal, contribute to more-personalized treatment. This report provides insight on how treatment options for colorectal cancer are likely to change over the 2019-2029 forecast period. It also analyzes the current and future earnings potential of drugs already in the market and those expected to be approved for colorectal cancer.
Questions answered:
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 20 country-specific interviews with thought leaders.
Epidemiology: Diagnosed incident cases of stage I, II, III, and IV colorectal cancer.
Population segments in market forecast:Stage II colon cancer;stage II rectal cancer;stage III colon cancer;stage III rectal cancer;stage IV colorectal cancer wild-type BRAF and RAS, first-line (left-sided);stage IV colorectal cancer wild-type BRAF and RAS, first-line (right-sided);stage IV colorectal cancer mutant RAS, first-line;stage IV colorectal cancer mutant BRAF, first-line;stage IV colorectal cancer wild-type BRAF and RAS, second-line (left-sided); stage IV colorectal cancer wild-type BRAF and RAS, second-line (right-sided); stage IV colorectal cancer mutant RAS, second-line; stage IV colorectal cancer mutant BRAF, second-line; stage IV colorectal cancer wild-type BRAF and RAS, third-line (left-sided); stage IV colorectal cancer wild-type BRAF and RAS, third-line (right-sided); stage IV colorectal cancer mutant RAS, third-line; stage IV colorectal cancer mutant BRAF.
Emerging therapies: Phase III: 7 drugs; Phase I-II: 9 drugs.